Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of QPI-1002 to prevent delayed graft function after older donor kidney transplant
2015-003078-33Phase 3Completed
- Sponsor
- Quark Pharmaceuticals
- Start
- Mar 2016
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in delayed graft function (DGF) comparing QPI-1002 with Placebo (2 arms). Primary endpoint: Delayed graft function. Started Mar 2016; status: completed.
02
Drugs
teprasiran
03
Conditions
delayed graft function (DGF)
Beyond the preview
Go deeper on 2015-003078-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-003078-33.